Phase I Evaluation of Desbutyihalofantrine in Healthy Volunteers

摘要

Halofantrine HCl is an antimalarial drug approved by the FDA for the treatment of mild to moderate malaria caused by Plasm odium falciparum or Plasm odium vivax(l). The present study was designed to investigate the safety, tolerance and pharmacokinetics of halofantrine HCI given in multiple doses in a Phase I study as part of the overall development of halofantrine as a prophylactic antimalarial drug.